Actinium Pharmaceuticals Inc (ATNM)

$1.45 0.00 (N/A)
Market Cap 43.05M
Revenue (ttm) 0.00
Net Income (ttm) -38.24M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 82,200
Avg Vol 230,194
Day's Range N/A - N/A
Shares Out 31.20M
Stochastic %K 87%
Beta -0.37
Analysts Strong Sell
Price Target $5.00

Company Profile

Actinium Pharmaceuticals, Inc. develops antibody radiation conjugates and other targeted radiotherapies intended to improve outcomes for people who have failed existing oncology therapies. The company advances two clinical stage product candidates, Actimab-A, to treat patients with myeloid malignancies including acute myeloid leukemia and myelodysplastic syndromes; and Iomab-ACT, to improve patient access to and outcomes with cellular therapies, such as CAR-T for various blood cancer indications...

Industry: Biotechnology
Sector: Healthcare
Phone: 646 677 3870
Address:
100 Park Avenue, 23rd Floor, New York, United States
Pickerbefore
Pickerbefore Dec. 5 at 2:44 PM
$ATNM did Seth create any stock value this week? NO. Will he take his big paycheck this week? YES. I can’t wait till the dummy is gone. Ten years and NOTHING.
0 · Reply
gooddoggie
gooddoggie Dec. 4 at 6:40 PM
$ATNM Don’t worry it will be over soon.
0 · Reply
dm4
dm4 Dec. 4 at 12:44 PM
$ATNM ARCs are definitely here to stay but a lot of new developments also happening. ATNM, with all the past baggage, needs to move fast before ARCS loose their glamour and value! “New cancer therapy hunts and destroys deadly tumors in major breakthrough study” https://www.yahoo.com/news/articles/cancer-therapy-hunts-destroys-deadly-120025545.html
1 · Reply
noggindog
noggindog Dec. 4 at 11:37 AM
$ATNM All we hear about is possibilities. Enough with the potential energy, let’s see some kinetic energy…get moving!!!
0 · Reply
alcacer123
alcacer123 Dec. 4 at 9:02 AM
$ATNM Actinium is about to launch its industrial-grade AC225. Key advantages include the product's extremely high purity and low production cost. Demand for AC225 is starting to grow, and new suppliers are also beginning to enter the market.
0 · Reply
yellowjacker
yellowjacker Dec. 3 at 11:40 PM
$ATNM To be clear Eckert & Zeigler (EZAG) owns the cyclotron Technology in the probuction process and the plant which will be coming on line. Actinium Pharama owns 45 patent portfolio on how AC-225 is to be used in target radiotherapies on how to combine Ac-225 payloads, targeting agents,linkers, doses, and methods of use. What they also own is the IP methods to be use to create or manufacture the AC-225 for cancer use. Alot of Pharma will have to come through Actinium pharma to use AC-225 at the commerical grade level to enhance treatments, do to their strong patent protection.
2 · Reply
Snookville
Snookville Dec. 3 at 7:51 PM
$ATNM Come on gang!
0 · Reply
johnny4cures
johnny4cures Dec. 3 at 6:54 PM
$ATNM Good info here
0 · Reply
johnny4cures
johnny4cures Dec. 3 at 6:53 PM
$ATNM People underestimate what is coming for ATNM-400. FDA lets go get this ATNM-400 train moving!
0 · Reply
johnny4cures
johnny4cures Dec. 3 at 6:49 PM
$ATNM Actinium Pharma To Present Preclinical Data For ATNM-400, Actinium-225 Antibody Radioconjugate, In HR+, HER2+ And Triple-Negative Breast Cancer At SABCS 2025 https://www.webullapp.com/news-detail/13951951253455872?__app_cfg__=%7B%22supportTheme%22%3Atrue%7D&sourcePage=Stock_NewsList&tickerId=913303716&audioNewsPlayedDuration=&theme=1&color=2&hl=en&android_sdk_int=36&canary-version=&_v=1&sp=1&statusBarHeightV2=29&isLite=false&wbFontSetting=standard&wbFontUnit=29&wbFontSize=29&isSubsNews=false
1 · Reply
Latest News on ATNM
Actinium Pharmaceuticals Announces ATNM-400 Data Demonstrating Potent Efficacy in Triple-Negative Breast Cancer and Ability to Overcome Endocrine and HER2-Targeted Therapy Resistance Being Presented at the San Antonio Breast Cancer Symposium

Dec 1, 2025, 8:45 AM EST - 4 days ago

Actinium Pharmaceuticals Announces ATNM-400 Data Demonstrating Potent Efficacy in Triple-Negative Breast Cancer and Ability to Overcome Endocrine and HER2-Targeted Therapy Resistance Being Presented at the San Antonio Breast Cancer Symposium

The Race for the Global Radiotherapy Cancer Market; Actinium Pharmaceuticals' (ATNM) Big Bet

Nov 17, 2025, 8:30 AM EST - 18 days ago

The Race for the Global Radiotherapy Cancer Market; Actinium Pharmaceuticals' (ATNM) Big Bet

NVS

Actinium Announces Superior Anti-Tumor Activity of ATNM-400 in Lung Cancer Compared to the Leading First, Second and Third-Line Approved EGFR Mutant Therapies and Mechanistic Synergy with Osimertinib at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

Oct 27, 2025, 7:00 AM EDT - 5 weeks ago

Actinium Announces Superior Anti-Tumor Activity of ATNM-400 in Lung Cancer Compared to the Leading First, Second and Third-Line Approved EGFR Mutant Therapies and Mechanistic Synergy with Osimertinib at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

Actinium Pharmaceuticals Presents New Data Demonstrating Potent and Durable Efficacy of ATNM-400, a First-in-Class Multi-Tumor Actinium-225 Radiotherapy, at the 32nd Annual Prostate Cancer Foundation Scientific Retreat

Oct 24, 2025, 8:30 AM EDT - 6 weeks ago

Actinium Pharmaceuticals Presents New Data Demonstrating Potent and Durable Efficacy of ATNM-400, a First-in-Class Multi-Tumor Actinium-225 Radiotherapy, at the 32nd Annual Prostate Cancer Foundation Scientific Retreat

Actinium Pharmaceuticals to Unveil the Multi-Tumor Potential of ATNM-400, a First-in-Class Actinium-225 Radiotherapy, with Data in Non-Small Cell Lung Cancer at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

Oct 13, 2025, 12:10 PM EDT - 7 weeks ago

Actinium Pharmaceuticals to Unveil the Multi-Tumor Potential of ATNM-400, a First-in-Class Actinium-225 Radiotherapy, with Data in Non-Small Cell Lung Cancer at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

Actinium to Present ATNM-400 Preclinical Data Highlighting Durable Tumor Control and Ability to Overcome Resistance to Standard-of-Care Prostate Cancer Therapies at the 32nd Annual Prostate Cancer Foundation Scientific Retreat

Oct 13, 2025, 8:30 AM EDT - 7 weeks ago

Actinium to Present ATNM-400 Preclinical Data Highlighting Durable Tumor Control and Ability to Overcome Resistance to Standard-of-Care Prostate Cancer Therapies at the 32nd Annual Prostate Cancer Foundation Scientific Retreat

Actinium Presents Data Supporting Paradigm Changing Potential of ATNM-400 in Prostate Cancer Demonstrating Its Superior Efficacy and Improved Survival in Treatment Resistant Tumor Models versus Pluvicto and ARPI Therapy, and Also Enhanced Efficacy in Combination with ARPI Therapy at the 4th Annual Targeted Radiopharmaceuticals Summit

Jul 31, 2025, 8:30 AM EDT - 4 months ago

Actinium Presents Data Supporting Paradigm Changing Potential of ATNM-400 in Prostate Cancer Demonstrating Its Superior Efficacy and Improved Survival in Treatment Resistant Tumor Models versus Pluvicto and ARPI Therapy, and Also Enhanced Efficacy in Combination with ARPI Therapy at the 4th Annual Targeted Radiopharmaceuticals Summit

Actinium Highlights Expanded Data Set for ATNM-400 in Prostate Cancer Demonstrating Superior Efficacy to Enzalutamide and Ability to Overcome Resistance to ARPI Therapy and PSMA-Ac-225/Lu-177 Labelled Radiotherapy at the Society of Nuclear Medicine & Molecular Imaging Annual Meeting

Jun 23, 2025, 11:30 AM EDT - 5 months ago

Actinium Highlights Expanded Data Set for ATNM-400 in Prostate Cancer Demonstrating Superior Efficacy to Enzalutamide and Ability to Overcome Resistance to ARPI Therapy and PSMA-Ac-225/Lu-177 Labelled Radiotherapy at the Society of Nuclear Medicine & Molecular Imaging Annual Meeting

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of May 27, 2025 in Actinium Lawsuit - ATNM

May 22, 2025, 5:45 AM EDT - 7 months ago

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of May 27, 2025 in Actinium Lawsuit - ATNM

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of May 27, 2025 in Actinium Lawsuit – ATNM

May 15, 2025, 1:43 PM EDT - 7 months ago

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of May 27, 2025 in Actinium Lawsuit – ATNM

INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Actinium

May 14, 2025, 1:26 PM EDT - 7 months ago

INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Actinium

Actinium Announces Enrollment of First Patient in the Iomab-ACT Commercial CAR-T Trial at the University of Texas Southwestern Medical Center

May 6, 2025, 8:45 AM EDT - 7 months ago

Actinium Announces Enrollment of First Patient in the Iomab-ACT Commercial CAR-T Trial at the University of Texas Southwestern Medical Center

Lawsuit for Investors in shares of Actinium Pharmaceuticals, Inc. (NYSE: ATNM) announced by the Shareholders Foundation

Apr 30, 2025, 7:25 AM EDT - 7 months ago

Lawsuit for Investors in shares of Actinium Pharmaceuticals, Inc. (NYSE: ATNM) announced by the Shareholders Foundation

Actinium Presents Data Showing ATNM-400 is More Efficacious than Pluvicto and is Highly Efficacious after Pluvicto Resistance in Prostate Cancer Tumor Models at the American Association for Cancer Research Annual Meeting

Apr 28, 2025, 8:30 AM EDT - 7 months ago

Actinium Presents Data Showing ATNM-400 is More Efficacious than Pluvicto and is Highly Efficacious after Pluvicto Resistance in Prostate Cancer Tumor Models at the American Association for Cancer Research Annual Meeting

Actinium Highlights Mutation Agnostic Antileukemic Activity of Actimab-A Against FLT3, NPM1, KMT2A and TP53 Mutations in AML Models Demonstrating Backbone Potential for Acute Myeloid Leukemia Treatment at the American Association for Cancer Research Annual Meeting

Apr 28, 2025, 8:00 AM EDT - 7 months ago

Actinium Highlights Mutation Agnostic Antileukemic Activity of Actimab-A Against FLT3, NPM1, KMT2A and TP53 Mutations in AML Models Demonstrating Backbone Potential for Acute Myeloid Leukemia Treatment at the American Association for Cancer Research Annual Meeting

ITM and Alpha-9 Oncology Enter Into Supply Agreement for Therapeutic Medical Radioisotope Actinium-225

Apr 24, 2025, 5:00 AM EDT - 8 months ago

ITM and Alpha-9 Oncology Enter Into Supply Agreement for Therapeutic Medical Radioisotope Actinium-225

SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Actinium

Apr 19, 2025, 8:20 AM EDT - 8 months ago

SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Actinium

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of May 27, 2025 in Actinium Pharmaceuticals, Inc. Lawsuit - ATNM

Apr 17, 2025, 5:45 AM EDT - 8 months ago

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of May 27, 2025 in Actinium Pharmaceuticals, Inc. Lawsuit - ATNM

Ibotta, Inc. Investors: Company Investigated by the Portnoy Law Firm

Apr 16, 2025, 10:01 AM EDT - 8 months ago

Ibotta, Inc. Investors: Company Investigated by the Portnoy Law Firm

IBTA

Pickerbefore
Pickerbefore Dec. 5 at 2:44 PM
$ATNM did Seth create any stock value this week? NO. Will he take his big paycheck this week? YES. I can’t wait till the dummy is gone. Ten years and NOTHING.
0 · Reply
gooddoggie
gooddoggie Dec. 4 at 6:40 PM
$ATNM Don’t worry it will be over soon.
0 · Reply
dm4
dm4 Dec. 4 at 12:44 PM
$ATNM ARCs are definitely here to stay but a lot of new developments also happening. ATNM, with all the past baggage, needs to move fast before ARCS loose their glamour and value! “New cancer therapy hunts and destroys deadly tumors in major breakthrough study” https://www.yahoo.com/news/articles/cancer-therapy-hunts-destroys-deadly-120025545.html
1 · Reply
noggindog
noggindog Dec. 4 at 11:37 AM
$ATNM All we hear about is possibilities. Enough with the potential energy, let’s see some kinetic energy…get moving!!!
0 · Reply
alcacer123
alcacer123 Dec. 4 at 9:02 AM
$ATNM Actinium is about to launch its industrial-grade AC225. Key advantages include the product's extremely high purity and low production cost. Demand for AC225 is starting to grow, and new suppliers are also beginning to enter the market.
0 · Reply
yellowjacker
yellowjacker Dec. 3 at 11:40 PM
$ATNM To be clear Eckert & Zeigler (EZAG) owns the cyclotron Technology in the probuction process and the plant which will be coming on line. Actinium Pharama owns 45 patent portfolio on how AC-225 is to be used in target radiotherapies on how to combine Ac-225 payloads, targeting agents,linkers, doses, and methods of use. What they also own is the IP methods to be use to create or manufacture the AC-225 for cancer use. Alot of Pharma will have to come through Actinium pharma to use AC-225 at the commerical grade level to enhance treatments, do to their strong patent protection.
2 · Reply
Snookville
Snookville Dec. 3 at 7:51 PM
$ATNM Come on gang!
0 · Reply
johnny4cures
johnny4cures Dec. 3 at 6:54 PM
$ATNM Good info here
0 · Reply
johnny4cures
johnny4cures Dec. 3 at 6:53 PM
$ATNM People underestimate what is coming for ATNM-400. FDA lets go get this ATNM-400 train moving!
0 · Reply
johnny4cures
johnny4cures Dec. 3 at 6:49 PM
$ATNM Actinium Pharma To Present Preclinical Data For ATNM-400, Actinium-225 Antibody Radioconjugate, In HR+, HER2+ And Triple-Negative Breast Cancer At SABCS 2025 https://www.webullapp.com/news-detail/13951951253455872?__app_cfg__=%7B%22supportTheme%22%3Atrue%7D&sourcePage=Stock_NewsList&tickerId=913303716&audioNewsPlayedDuration=&theme=1&color=2&hl=en&android_sdk_int=36&canary-version=&_v=1&sp=1&statusBarHeightV2=29&isLite=false&wbFontSetting=standard&wbFontUnit=29&wbFontSize=29&isSubsNews=false
1 · Reply
yellowjacker
yellowjacker Dec. 3 at 6:33 PM
$ATNM Remember Ac-225 is a commodity. The plant in Indiana will produce the highest purity of Ac-225 at the lowest cost. $ATNM will be first in line to be supplied with Ac-225 for their trails and once the plant is running at 100% the rest will be farm out at a profit. The only set back that could happen is during the goverment shut down the plant operation may not had been totally certified. The plan was to have it up and running in December 2025.
2 · Reply
Biotrad3r
Biotrad3r Dec. 3 at 6:31 PM
$ATNM TOPBIG aka Mnewbie, Timfris, tjm1… Same shortung script. ”If the pipeline is so good, why hasnt it been bought out yet?” This is not even a valid argument against the science. More like an elementary school playground taunt
1 · Reply
Pickerbefore
Pickerbefore Dec. 3 at 2:26 PM
$ATNM nothing but BS so they can continue drawing big bucks. Pathetic management.
0 · Reply
timfris
timfris Dec. 3 at 2:03 PM
$ATNM did you really believe them? Jesus. There’s well run bios out there with approved drugs or at the very least, a non crooked CEO and CFO.
0 · Reply
gooddoggie
gooddoggie Dec. 3 at 1:52 PM
$ATNM Top big basher.
0 · Reply
Xarevira
Xarevira Dec. 3 at 10:47 AM
$ATNM https://oncodaily.com/career/jeri-kim-420576
0 · Reply
TOPBIG5
TOPBIG5 Dec. 3 at 9:38 AM
$ATNM No cyclotron technology from Actinium. Melbourne (Australia) and Kyoto (Japan) | 21 November 2025 Telix today announces the official opening of Telix Manufacturing Solutions (TMS) in Yokohama, Japan, the Company’s first cyclotron facility in the Asia Pacific region (APAC). Our TMS Brussels South site with nine GMP lines, clean rooms, a radiopharmacy, and two cyclotrons across a 30,000 sq ft site is one of Europe’s largest radiopharmaceutical production facilities. https://telixpharma.com/news-views/telix-opens-tms-yokohama-in-japan-commemorative-lecture-held/
1 · Reply
TOPBIG5
TOPBIG5 Dec. 3 at 8:48 AM
$ATNM It's nice that you're putting so much effort into this. But the realities with Actinium are different. There is nowhere near a partner for any of the candidates in the pipeline. The pipeline is so good that Big Pharma isn't interested in it. What's more important at the moment is that we've all read the PR reports about Iomab-B. It was suggested that approval was possible. If it turns out that this representation was incorrect, I cannot imagine that the court will not pursue this. Then things get uncomfortable for Actinium.
0 · Reply
Biotrad3r
Biotrad3r Dec. 3 at 5:12 AM
$ATNM its like Immedica fell off the face of the planet
0 · Reply
gooddoggie
gooddoggie Dec. 2 at 12:35 PM
$ATNM I’ve got a hunch it will close at $10 today. It’s possible I’m wrong. Or maybe that hunch is actually IBS acting up.
0 · Reply
luzongeezer
luzongeezer Dec. 2 at 11:31 AM
$ATNM LIFE IS BUT A DREAM WITHIN A DREAM. Come in, doggie.
2 · Reply
tjm1
tjm1 Dec. 2 at 10:18 AM
$ATNM In this for 12 years and still the only "break throughs" are all pre-clinical. The treatments that pass PH3 testing just disappear and this isn't a scam?
2 · Reply